The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features

Mieko Ochi; Shingo Miyamoto; Yuriko Terada; Yoshiaki Furuhata; Nobuyasu Awano; Takehiro Izumo; Soichiro Ikushima; Yuan Bae; Toshio Kumasaka; Hideo Kunito

doi:10.2169/internalmedicine.0002-17

CASE REPORTS

The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features

Mieko Ochi, Shingo Miyamoto, Yuriko Terada, Yoshiaki Furuhata, Nobuyasu Awano, Takehiro Izumo, Soichiro Ikushima, Yuan Bae, Toshio Kumasaka, Hideo Kunito

Author information

Mieko Ochi
Department of Medical Oncology, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Shingo Miyamoto
Department of Medical Oncology, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Yuriko Terada
Department of Thoracic Surgery, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Yoshiaki Furuhata
Department of Thoracic Surgery, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Nobuyasu Awano
Department of Respiratory Medicine, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Takehiro Izumo
Department of Respiratory Medicine, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Soichiro Ikushima
Department of Respiratory Medicine, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Yuan Bae
Department of Pathology, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Toshio Kumasaka
Department of Pathology, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan
Hideo Kunito
Department of Medical Oncology, Nihon Sekijujisha Iryo Center (Japanese Red Cross Medical Center), Japan

Keywords: nivolumab, choriocarcinoma, PD-1, PD-L1, acquisition of resistance

JOURNAL OPEN ACCESS

2018 Volume 57 Issue 12 Pages 1773-1777

DOI https://doi.org/10.2169/internalmedicine.0002-17

Browse “Advance online publication” version

Details

Abstract

We report the case of a 60-year-old Japanese man with a metastatic brain tumor that caused ataxia. As a consequence of resection of a cerebellar tumor, the tumor was diagnosed as a poorly differentiated adenocarcinoma with choriocarcinomatous features. The patient underwent bronchoscopy, leading to a diagnosis of the same histology as the brain tumor. After the administration of first-line chemotherapy and maintenance therapy due to progressive disease, he was given nivolumab and obtained a partial response; however, 11-months later, computed tomography showed tumor progression. Our experience suggests that nivolumab has strong activity, even in patients with a rare form of lung cancer.

Corresponding author

Register with J-STAGE for free!